{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T18:00:06Z","timestamp":1787162406526,"version":"build-2736575974"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2022,11,5]],"date-time":"2022-11-05T00:00:00Z","timestamp":1667606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,5]],"date-time":"2022-11-05T00:00:00Z","timestamp":1667606400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Data indicate that the use of prophylactic granulocyte colony-stimulating factors (G-CSFs) for chemotherapy-induced febrile neutropenia (FN) in routine practice is not consistent with guideline recommendations. The initiative \u201csupportive care for febrile neutropenia prevention and appropriateness of G-CFS use\u201d was undertaken to address the issue of inappropriate prescription of G-CSFs and to improve guideline adherence in the treatment of FN.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In a two-round Delphi procedure, 36 medical oncologists reviewed clinically relevant recommendations on risk assessment, the appropriate use of G-CSFs, and the prevention of FN based on available literature and individual clinical expertise.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The consensus was reached on 16 out of 38 recommendations, which are backed by evidence from randomised clinical trials and routine clinical practice. The medical oncologists agreed that the severity of neutropenia depends on patients\u2019 characteristics and chemotherapy intensity, and therefore, the risk of severe neutropenia or FN should be assessed at each chemotherapy cycle so as to initiate prophylaxis with G-CSFs if required. The use of biosimilar G-CSFs, with similar efficacy and safety profiles to the originator biologic, has improved the availability and sustainability of cancer care. The timing of supportive therapy is crucial; for example, long-acting G-CSF should be administered 24\u201372\u00a0h after chemotherapy administration. Each biological agent has a recommended administration dose and duration, and it is important to follow these recommendations to avoid complications associated with under-prophylaxis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>It is hoped that these statements will help to increase adherence to guideline recommendations for appropriate G-CSF use and improve patient care.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00520-022-07430-7","type":"journal-article","created":{"date-parts":[[2022,11,5]],"date-time":"2022-11-05T04:02:48Z","timestamp":1667620968000},"page":"9877-9888","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Supportive therapies in the prevention of chemotherapy-induced febrile neutropenia and appropriate use of granulocyte colony-stimulating factors: a Delphi consensus statement"],"prefix":"10.1007","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2074-2418","authenticated-orcid":false,"given":"Vincenzo","family":"Adamo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3349-5604","authenticated-orcid":false,"given":"Lorenzo","family":"Antonuzzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Danova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9009-1572","authenticated-orcid":false,"given":"Michelino","family":"De Laurentiis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9064-8761","authenticated-orcid":false,"given":"Paolo","family":"Marchetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3159-5268","authenticated-orcid":false,"given":"Carmine","family":"Pinto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2097-2803","authenticated-orcid":false,"given":"Giovanni","family":"Rosti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,5]]},"reference":[{"issue":"3","key":"7430_CR1","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1093\/annonc\/mdj092","volume":"17","author":"Y Lalami","year":"2006","unstructured":"Lalami Y, Paesmans M, Muanza F et al (2006) Can we predict the duration of chemotherapy-induced neutropenia in febrile neutropenic patients, focusing on regimen-specific risk factors? A retrospective analysis. Ann Oncol 17(3):507\u2013514. https:\/\/doi.org\/10.1093\/annonc\/mdj092","journal-title":"Ann Oncol"},{"issue":"4","key":"7430_CR2","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1177\/0300891620927093","volume":"106","author":"AC Tralongo","year":"2020","unstructured":"Tralongo AC, Antonuzzo A, Pronzato P et al (2020) Management of chemotherapy-induced neutropenia in patients with cancer: 2019 guidelines of the Italian Medical Oncology Association (AIOM). Tumori 106(4):273\u2013280. https:\/\/doi.org\/10.1177\/0300891620927093","journal-title":"Tumori"},{"issue":"1","key":"7430_CR3","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s12094-018-1983-4","volume":"21","author":"A Carmona-Bayonas","year":"2019","unstructured":"Carmona-Bayonas A, Jimenez-Fonseca P, de Castro EM et al (2019) SEOM clinical practice guideline: management and prevention of febrile neutropenia in adults with solid tumors (2018). Clin Transl Oncol 21(1):75\u201386. https:\/\/doi.org\/10.1007\/s12094-018-1983-4","journal-title":"Clin Transl Oncol"},{"issue":"suppl 5","key":"7430_CR4","doi-asserted-by":"publisher","first-page":"v111","DOI":"10.1093\/annonc\/mdw325","volume":"27","author":"J Klastersky","year":"2016","unstructured":"Klastersky J, de Naurois J, Rolston K et al (2016) Management of febrile neutropaenia: ESMO clinical practice guidelines. Ann Oncol 27(suppl 5):v111\u2013v118. https:\/\/doi.org\/10.1093\/annonc\/mdw325","journal-title":"Ann Oncol"},{"issue":"30","key":"7430_CR5","doi-asserted-by":"publisher","first-page":"3043","DOI":"10.1200\/jco.18.00374","volume":"36","author":"RA Taplitz","year":"2018","unstructured":"Taplitz RA, Kennedy EB, Bow EJ et al (2018) Antimicrobial prophylaxis for adult patients with cancer-related immunosuppression: ASCO and IDSA clinical practice guideline update. J Clin Oncol 36(30):3043\u20133054. https:\/\/doi.org\/10.1200\/jco.18.00374","journal-title":"J Clin Oncol"},{"issue":"1","key":"7430_CR6","doi-asserted-by":"publisher","first-page":"12","DOI":"10.6004\/jnccn.2020.0002","volume":"18","author":"PS Becker","year":"2020","unstructured":"Becker PS, Griffiths EA, Alwan LM et al (2020) NCCN guidelines insights: hematopoietic growth factors, version 1.2020: featured updates to the NCCN guidelines. J Natl Compr Canc Netw 18(1):12\u201322. https:\/\/doi.org\/10.6004\/jnccn.2020.0002","journal-title":"J Natl Compr Canc Netw"},{"issue":"9","key":"7430_CR7","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1002\/cncr.25691","volume":"117","author":"GH Lyman","year":"2011","unstructured":"Lyman GH, Kuderer NM, Crawford J et al (2011) Predicting individual risk of neutropenic complications in patients receiving cancer chemotherapy. Cancer 117(9):1917\u20131927. https:\/\/doi.org\/10.1002\/cncr.25691","journal-title":"Cancer"},{"issue":"Supplement 1","key":"7430_CR8","doi-asserted-by":"publisher","first-page":"5186","DOI":"10.1182\/blood-2018-99-116971","volume":"132","author":"A Gill","year":"2018","unstructured":"Gill A, Hussaini S, Gosain R et al (2018) Frequency of infection source and predictors of mortality in leukemia patients diagnosed with febrile neutropenia. Blood 132(Supplement 1):5186\u20135186. https:\/\/doi.org\/10.1182\/blood-2018-99-116971","journal-title":"Blood"},{"key":"7430_CR9","doi-asserted-by":"publisher","first-page":"37","DOI":"10.5495\/wjcid.v6.i3.37","volume":"6","author":"J Klastersky","year":"2016","unstructured":"Klastersky J, Paesmans M, Aoun M et al (2016) Clinical research in febrile neutropenia in cancer patients: past achievements and perspectives for the future. World J Clin Infect Dis 6:37. https:\/\/doi.org\/10.5495\/wjcid.v6.i3.37","journal-title":"World J Clin Infect Dis"},{"issue":"23","key":"7430_CR10","doi-asserted-by":"publisher","first-page":"5555","DOI":"10.1002\/cncr.25332","volume":"116","author":"GH Lyman","year":"2010","unstructured":"Lyman GH, Michels SL, Reynolds MW, Barron R, Tomic KS, Yu J (2010) Risk of mortality in patients with cancer who experience febrile neutropenia. Cancer 116(23):5555\u20135563. https:\/\/doi.org\/10.1002\/cncr.25332","journal-title":"Cancer"},{"issue":"1","key":"7430_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/MOH.0b013e328340dc51","volume":"18","author":"GH Lyman","year":"2011","unstructured":"Lyman GH (2011) A comparison of international guidelines for the prevention of chemotherapy-induced neutropenia. Curr Opin Hematol 18(1):1\u201310. https:\/\/doi.org\/10.1097\/MOH.0b013e328340dc51","journal-title":"Curr Opin Hematol"},{"key":"7430_CR12","unstructured":"U.S. Food & Drug Administration. Pegfilgrastim-jmdb label information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/761075s000lbl.pdf. Accessed August 24 2021"},{"issue":"7","key":"7430_CR13","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1001\/jamainternmed.2013.2921","volume":"173","author":"JD Wright","year":"2013","unstructured":"Wright JD, Neugut AI, Ananth CV et al (2013) Deviations from guideline-based therapy for febrile neutropenia in cancer patients and their effect on outcomes. JAMA Intern Med 173(7):559\u2013568. https:\/\/doi.org\/10.1001\/jamainternmed.2013.2921","journal-title":"JAMA Intern Med"},{"issue":"6","key":"7430_CR14","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1177\/1078155219896396","volume":"26","author":"B Jansma","year":"2020","unstructured":"Jansma B, Vakkalanka P, Talan DA, Negaard B, Faine BA (2020) Guideline adherence for the management of emergency department patients with febrile neutropenia and no infection source: is there room for improvement? J Oncol Pharm Pract 26(6):1382\u20131389. https:\/\/doi.org\/10.1177\/1078155219896396","journal-title":"J Oncol Pharm Pract"},{"key":"7430_CR15","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.critrevonc.2017.11.005","volume":"120","author":"Y Lalami","year":"2017","unstructured":"Lalami Y, Klastersky J (2017) Impact of chemotherapy-induced neutropenia (CIN) and febrile neutropenia (FN) on cancer treatment outcomes: an overview about well-established and recently emerging clinical data. Crit Rev Oncol Hematol 120:163\u2013179. https:\/\/doi.org\/10.1016\/j.critrevonc.2017.11.005","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"7430_CR16","doi-asserted-by":"publisher","first-page":"10","DOI":"10.7275\/pdz9-th90","volume":"12","author":"C-C Hsu","year":"2007","unstructured":"Hsu C-C, Sandford BA (2007) The Delphi technique: making sense of consensus. Pract Assess Res Eval 12(1):10. https:\/\/doi.org\/10.7275\/pdz9-th90","journal-title":"Pract Assess Res Eval"},{"issue":"4","key":"7430_CR17","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1007\/s00520-019-05001-x","volume":"28","author":"H Nomura","year":"2020","unstructured":"Nomura H, Hatogai K, Maki Y et al (2020) Risk factors for febrile neutropenia in neoadjuvant docetaxel, cisplatin, and 5-fluorouracil chemotherapy for esophageal cancer. Support Care Cancer 28(4):1849\u20131854. https:\/\/doi.org\/10.1007\/s00520-019-05001-x","journal-title":"Support Care Cancer"},{"issue":"7","key":"7430_CR18","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1007\/s40265-018-0909-3","volume":"78","author":"PM Kasi","year":"2018","unstructured":"Kasi PM, Grothey A (2018) Chemotherapy-induced neutropenia as a prognostic and predictive marker of outcomes in solid-tumor patients. Drugs 78(7):737\u2013745. https:\/\/doi.org\/10.1007\/s40265-018-0909-3","journal-title":"Drugs"},{"issue":"8","key":"7430_CR19","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1093\/jjco\/hyaa047","volume":"50","author":"M Mayama","year":"2020","unstructured":"Mayama M, Asano H, Nomura E et al (2020) Four versus six chemotherapy cycles in endometrial carcinoma with a high risk of recurrence: a retrospective study. Jpn J Clin Oncol 50(8):882\u2013888. https:\/\/doi.org\/10.1093\/jjco\/hyaa047","journal-title":"Jpn J Clin Oncol"},{"issue":"6","key":"7430_CR20","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1208\/s12248-020-00529-x","volume":"22","author":"W Chen","year":"2020","unstructured":"Chen W, Boras B, Sung T, Hu W, Spilker ME, D\u2019Argenio DZ (2020) Predicting chemotherapy-induced neutropenia and granulocyte colony-stimulating factor response using model-based in vitro to clinical translation. AAPS J 22(6):143. https:\/\/doi.org\/10.1208\/s12248-020-00529-x","journal-title":"AAPS J"},{"issue":"7","key":"7430_CR21","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.1007\/s00520-019-04773-6","volume":"27","author":"P Chambers","year":"2019","unstructured":"Chambers P, Jani Y, Wei L, Kipps E, Forster MD, Wong ICK (2019) Patient factors and their impact on neutropenic events: a systematic review and meta-analysis. Support Care Cancer 27(7):2413\u20132424. https:\/\/doi.org\/10.1007\/s00520-019-04773-6","journal-title":"Support Care Cancer"},{"issue":"2","key":"7430_CR22","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1007\/s00520-019-04879-x","volume":"28","author":"E Aras","year":"2020","unstructured":"Aras E, Bayraktar-Ekincioglu A, Kilickap S (2020) Risk assessment of febrile neutropenia and evaluation of G-CSF use in patients with cancer: a real-life study. Support Care Cancer 28(2):691\u2013699. https:\/\/doi.org\/10.1007\/s00520-019-04879-x","journal-title":"Support Care Cancer"},{"issue":"11","key":"7430_CR23","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1016\/s1470-2045(20)30453-8","volume":"21","author":"M Provencio","year":"2020","unstructured":"Provencio M, Nadal E, Insa A et al (2020) Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial. Lancet Oncol 21(11):1413\u20131422. https:\/\/doi.org\/10.1016\/s1470-2045(20)30453-8","journal-title":"Lancet Oncol"},{"key":"7430_CR24","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.ejca.2016.05.011","volume":"63","author":"KA Klute","year":"2016","unstructured":"Klute KA, Brouwer J, Jhawer M et al (2016) Chemotherapy dose intensity predicted by baseline nutrition assessment in gastrointestinal malignancies: a multicentre analysis. Eur J Cancer 63:189\u2013200. https:\/\/doi.org\/10.1016\/j.ejca.2016.05.011","journal-title":"Eur J Cancer"},{"issue":"1","key":"7430_CR25","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1093\/annonc\/mdg013","volume":"14","author":"J Alexandre","year":"2003","unstructured":"Alexandre J, Gross-Goupil M, Falissard B et al (2003) Evaluation of the nutritional and inflammatory status in cancer patients for the risk assessment of severe haematological toxicity following chemotherapy. Ann Oncol 14(1):36\u201341. https:\/\/doi.org\/10.1093\/annonc\/mdg013","journal-title":"Ann Oncol"},{"issue":"5","key":"7430_CR26","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1177\/1078155218776471","volume":"25","author":"JM Collins","year":"2019","unstructured":"Collins JM, Fleming GF, Christ TN (2019) Comparison of the incidence of febrile neutropenia in obese and normal weight breast cancer patients receiving myelosuppressive chemotherapy and prophylactic pegfilgrastim. J Oncol Pharm Pract 25(5):1112\u20131118. https:\/\/doi.org\/10.1177\/1078155218776471","journal-title":"J Oncol Pharm Pract"},{"issue":"1","key":"7430_CR27","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.pan.2018.11.001","volume":"19","author":"Y Kurita","year":"2019","unstructured":"Kurita Y, Kobayashi N, Tokuhisa M et al (2019) Sarcopenia is a reliable prognostic factor in patients with advanced pancreatic cancer receiving FOLFIRINOX chemotherapy. Pancreatology 19(1):127\u2013135. https:\/\/doi.org\/10.1016\/j.pan.2018.11.001","journal-title":"Pancreatology"},{"issue":"3","key":"7430_CR28","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1097\/COC.0000000000000514","volume":"42","author":"S Ball","year":"2019","unstructured":"Ball S, Brown TJ, Das A, Khera R, Khanna S, Gupta A (2019) Effect of neutropenic diet on infection rates in cancer patients with neutropenia. Am J Clin Oncol 42(3):270\u2013274. https:\/\/doi.org\/10.1097\/COC.0000000000000514","journal-title":"Am J Clin Oncol"},{"issue":"11","key":"7430_CR29","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1111\/imj.14712","volume":"50","author":"W Cui","year":"2020","unstructured":"Cui W, Shingleton J, Byrne L et al (2020) Dose modification for haematological toxicity: a survey of Australian medical oncologists. Intern Med J 50(11):1338\u20131343. https:\/\/doi.org\/10.1111\/imj.14712","journal-title":"Intern Med J"},{"issue":"16_suppl","key":"7430_CR30","doi-asserted-by":"publisher","first-page":"8117","DOI":"10.1200\/jco.2005.23.16_suppl.8117","volume":"23","author":"NM Kuderer","year":"2005","unstructured":"Kuderer NM, Crawford J, Dale DC, Lyman GH (2005) Meta-analysis of prophylactic granulocyte colony-stimulating factor (G-CSF) in cancer patients receiving chemotherapy. J Clin Oncol 23(16_suppl):8117\u20138117. https:\/\/doi.org\/10.1200\/jco.2005.23.16_suppl.8117","journal-title":"J Clin Oncol"},{"issue":"18","key":"7430_CR31","doi-asserted-by":"publisher","first-page":"4198","DOI":"10.1200\/JCO.2005.05.645","volume":"23","author":"OA Clark","year":"2005","unstructured":"Clark OA, Lyman GH, Castro AA, Clark LG, Djulbegovic B (2005) Colony-stimulating factors for chemotherapy-induced febrile neutropenia: a meta-analysis of randomized controlled trials. J Clin Oncol 23(18):4198\u20134214. https:\/\/doi.org\/10.1200\/JCO.2005.05.645","journal-title":"J Clin Oncol"},{"issue":"10","key":"7430_CR32","doi-asserted-by":"publisher","first-page":"2475","DOI":"10.1093\/annonc\/mdt226","volume":"24","author":"GH Lyman","year":"2013","unstructured":"Lyman GH, Dale DC, Culakova E et al (2013) The impact of the granulocyte colony-stimulating factor on chemotherapy dose intensity and cancer survival: a systematic review and meta-analysis of randomized controlled trials. Ann Oncol 24(10):2475\u20132484. https:\/\/doi.org\/10.1093\/annonc\/mdt226","journal-title":"Ann Oncol"},{"issue":"6","key":"7430_CR33","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1111\/bcp.14226","volume":"86","author":"A Bellon","year":"2020","unstructured":"Bellon A, Wang J, Skerjanec A et al (2020) A large multicentre, randomized, double-blind, cross-over study in healthy volunteers to compare pharmacokinetics, pharmacodynamics and safety of a pegfilgrastim biosimilar with its US- and EU-reference biologics. Br J Clin Pharmacol 86(6):1139\u20131149. https:\/\/doi.org\/10.1111\/bcp.14226","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"7430_CR34","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s40259-015-0124-7","volume":"29","author":"F S\u00f6rgel","year":"2015","unstructured":"S\u00f6rgel F, Schwebig A, Holzmann J, Prasch S, Singh P, Kinzig M (2015) Comparability of biosimilar filgrastim with originator filgrastim: protein characterization, pharmacodynamics, and pharmacokinetics. BioDrugs 29(2):123\u2013131. https:\/\/doi.org\/10.1007\/s40259-015-0124-7","journal-title":"BioDrugs"},{"issue":"2","key":"7430_CR35","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s40259-019-00343-8","volume":"33","author":"HM Yao","year":"2019","unstructured":"Yao HM, Ottery FD, Borema T et al (2019) PF-06881893 (Nivestym\u2122), a filgrastim biosimilar, versus US-licensed filgrastim reference product (US-Neupogen(\u00ae)): pharmacokinetics, pharmacodynamics, immunogenicity, and safety of single or multiple subcutaneous doses in healthy volunteers. BioDrugs 33(2):207\u2013220. https:\/\/doi.org\/10.1007\/s40259-019-00343-8","journal-title":"BioDrugs"},{"issue":"10","key":"7430_CR36","doi-asserted-by":"publisher","first-page":"4291","DOI":"10.1007\/s12325-020-01459-y","volume":"37","author":"B Finck","year":"2020","unstructured":"Finck B, Tang H, Civoli F, Hodge J, O\u2019Kelly H, Vexler V (2020) Pharmacokinetic and pharmacodynamic equivalence of pegfilgrastim-cbqv and pegfilgrastim in healthy subjects. Adv Ther 37(10):4291\u20134307. https:\/\/doi.org\/10.1007\/s12325-020-01459-y","journal-title":"Adv Ther"},{"issue":"2","key":"7430_CR37","first-page":"131","volume":"34","author":"V Bhatt","year":"2004","unstructured":"Bhatt V, Saleem A (2004) Review: drug-induced neutropenia-pathophysiology, clinical features, and management. Ann Clin Lab Sci 34(2):131\u2013137","journal-title":"Ann Clin Lab Sci"},{"issue":"11","key":"7430_CR38","doi-asserted-by":"publisher","first-page":"5085","DOI":"10.1007\/s00520-020-05603-w","volume":"28","author":"X Li","year":"2020","unstructured":"Li X, Zheng H, Yu MC et al (2020) Is PEGylated G-CSF superior to G-CSF in patients with breast cancer receiving chemotherapy? A systematic review and meta-analysis. Support Care Cancer 28(11):5085\u20135097. https:\/\/doi.org\/10.1007\/s00520-020-05603-w","journal-title":"Support Care Cancer"},{"issue":"3","key":"7430_CR39","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1111\/ecc.12043","volume":"22","author":"D Almenar Cubells","year":"2013","unstructured":"Almenar Cubells D, Bosch Roig C, Jim\u00e9nez Orozco E et al (2013) Effectiveness of daily versus non-daily granulocyte colony-stimulating factors in patients with solid tumours undergoing chemotherapy: a multivariate analysis of data from current practice. Eur J Cancer Care (Engl) 22(3):400\u2013412. https:\/\/doi.org\/10.1111\/ecc.12043","journal-title":"Eur J Cancer Care (Engl)"},{"issue":"9","key":"7430_CR40","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.1185\/030079907x219599","volume":"23","author":"L Pinto","year":"2007","unstructured":"Pinto L, Liu Z, Doan Q, Bernal M, Dubois R, Lyman G (2007) Comparison of pegfilgrastim with filgrastim on febrile neutropenia, grade IV neutropenia and bone pain: a meta-analysis of randomized controlled trials. Curr Med Res Opin 23(9):2283\u20132295. https:\/\/doi.org\/10.1185\/030079907x219599","journal-title":"Curr Med Res Opin"},{"issue":"5","key":"7430_CR41","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1177\/1078155215625459","volume":"22","author":"S Mitchell","year":"2016","unstructured":"Mitchell S, Li X, Woods M et al (2016) Comparative effectiveness of granulocyte colony-stimulating factors to prevent febrile neutropenia and related complications in cancer patients in clinical practice: a systematic review. J Oncol Pharm Pract 22(5):702\u2013716. https:\/\/doi.org\/10.1177\/1078155215625459","journal-title":"J Oncol Pharm Pract"},{"key":"7430_CR42","doi-asserted-by":"publisher","first-page":"e46","DOI":"10.14694\/EdBook_AM.2012.32.183","volume":"32","author":"TJ Smith","year":"2012","unstructured":"Smith TJ, Hillner BE, Kelly RJ (2012) Reducing the cost of cancer care: how to bend the curve downward. Am Soc Clin Oncol Educ Book 32:e46\u2013e51. https:\/\/doi.org\/10.14694\/EdBook_AM.2012.32.183","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"10","key":"7430_CR43","doi-asserted-by":"publisher","first-page":"cd003039","DOI":"10.1002\/14651858.CD003039.pub2","volume":"2014","author":"R Mhaskar","year":"2014","unstructured":"Mhaskar R, Clark OA, Lyman G, Engel Ayer Botrel T, MorgantiPaladini L, Djulbegovic B (2014) Colony-stimulating factors for chemotherapy-induced febrile neutropenia. Cochrane Database Syst Rev 2014(10):cd003039. https:\/\/doi.org\/10.1002\/14651858.CD003039.pub2","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"7430_CR44","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/s40273-016-0474-0","volume":"35","author":"K Fust","year":"2017","unstructured":"Fust K, Li X, Maschio M et al (2017) Cost-effectiveness analysis of prophylaxis treatment strategies to reduce the incidence of febrile neutropenia in patients with early-stage breast cancer or non-hodgkin lymphoma. Pharmacoeconomics 35(4):425\u2013438. https:\/\/doi.org\/10.1007\/s40273-016-0474-0","journal-title":"Pharmacoeconomics"},{"issue":"5","key":"7430_CR45","doi-asserted-by":"publisher","first-page":"2309","DOI":"10.1007\/s00520-015-3036-7","volume":"24","author":"D Weycker","year":"2016","unstructured":"Weycker D, Li X, Figueredo J, Barron R, Tzivelekis S, Hagiwara M (2016) Risk of chemotherapy-induced febrile neutropenia in cancer patients receiving pegfilgrastim prophylaxis: does timing of administration matter? Support Care Cancer 24(5):2309\u20132316. https:\/\/doi.org\/10.1007\/s00520-015-3036-7","journal-title":"Support Care Cancer"},{"key":"7430_CR46","unstructured":"Northern Cancer Alliance. Guideline for the use of granulocyte-colony stimulating factor (G-CSF) in adult oncology and haematology patients. 2018. https:\/\/www.northerncanceralliance.nhs.uk\/wp-content\/uploads\/2018\/11\/GCSF-Guidelines-Northern-Cancer-Alliance-January-2018-v1.5.pdf. Accessed 05 July 2022"},{"issue":"1","key":"7430_CR47","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1007\/s12032-013-0797-z","volume":"31","author":"S Barni","year":"2014","unstructured":"Barni S, Lorusso V, Giordano M et al (2014) A prospective observational study to evaluate G-CSF usage in patients with solid tumors receiving myelosuppressive chemotherapy in Italian clinical oncology practice. Med Oncol 31(1):797. https:\/\/doi.org\/10.1007\/s12032-013-0797-z","journal-title":"Med Oncol"},{"issue":"6","key":"7430_CR48","doi-asserted-by":"publisher","first-page":"2301","DOI":"10.1007\/s00520-018-4513-6","volume":"27","author":"H Ludwig","year":"2019","unstructured":"Ludwig H, Gasc\u00f3n P, Bokemeyer C et al (2019) Outcomes of chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar filgrastim (Zarzio\u00ae) initiated \u201csame-day\u201d(< 24 h), \u201cper-guidelines\u201d(24\u201372 h), and \u201clate\u201d(> 72 h): findings from the MONITOR-GCSF study. Support Care Cancer 27(6):2301\u20132312","journal-title":"Support Care Cancer"},{"issue":"11","key":"7430_CR49","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1007\/s12325-018-0798-6","volume":"35","author":"P Cornes","year":"2018","unstructured":"Cornes P, Gascon P, Chan S et al (2018) Systematic review and meta-analysis of short- versus long-acting granulocyte colony-stimulating factors for reduction of chemotherapy-induced febrile neutropenia. Adv Ther 35(11):1816\u20131829. https:\/\/doi.org\/10.1007\/s12325-018-0798-6","journal-title":"Adv Ther"},{"key":"7430_CR50","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ctarc.2017.11.003","volume":"14","author":"CC Billingsley","year":"2018","unstructured":"Billingsley CC, Cohn DE, Crim AK, Li Q, O\u2019Malley DM, Havrilesky LJ (2018) Is it reasonable to administer pegfilgrastim on day 1 of a myelosuppressive chemotherapy regimen? a cost-utility analysis. Cancer Treat Res Commun 14:21\u201325. https:\/\/doi.org\/10.1016\/j.ctarc.2017.11.003","journal-title":"Cancer Treat Res Commun"},{"issue":"4","key":"7430_CR51","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1007\/s00520-017-3959-2","volume":"26","author":"JJ Kirshner","year":"2018","unstructured":"Kirshner JJ, McDonald MC 3rd, Kruter F et al (2018) NOLAN: a randomized, phase 2 study to estimate the effect of prophylactic naproxen or loratadine vs no prophylactic treatment on bone pain in patients with early-stage breast cancer receiving chemotherapy and pegfilgrastim. Support Care Cancer 26(4):1323\u20131334. https:\/\/doi.org\/10.1007\/s00520-017-3959-2","journal-title":"Support Care Cancer"},{"issue":"1","key":"7430_CR52","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.critrevonc.2013.08.006","volume":"89","author":"M Lambertini","year":"2014","unstructured":"Lambertini M, Del Mastro L, Bellodi A, Pronzato P (2014) The five \u201cWs\u201d for bone pain due to the administration of granulocyte-colony stimulating factors (G-CSFs). Crit Rev Oncol Hematol 89(1):112\u2013128. https:\/\/doi.org\/10.1016\/j.critrevonc.2013.08.006","journal-title":"Crit Rev Oncol Hematol"},{"issue":"7","key":"7430_CR53","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1177\/1078155220910800","volume":"26","author":"J Nakamura","year":"2020","unstructured":"Nakamura J, Nishi TM, Yamashita S et al (2020) Pegfilgrastim-associated large-vessel vasculitis developed during adjuvant chemotherapy for breast cancer: a case report and review of the literature. J Oncol Pharm Pract 26(7):1785\u20131790. https:\/\/doi.org\/10.1177\/1078155220910800","journal-title":"J Oncol Pharm Pract"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-022-07430-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-022-07430-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-022-07430-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T08:26:38Z","timestamp":1669883198000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-022-07430-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,5]]},"references-count":53,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["7430"],"URL":"https:\/\/doi.org\/10.1007\/s00520-022-07430-7","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,5]]},"assertion":[{"value":"12 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This consensus study was approved by the review boards of the institutions of all scientific board members.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent to participate was obtained from the survey panel. The experts were informed that the survey results would be anonymised prior to discussion by the scientific board.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Informed consent for the results of the study to be published was obtained from the survey panel.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Vincenzo Adamo, during the past 3\u00a0years, received honoraria for consultant roles and\/or participation in advisory boards and\/or meetings by Amgen, AstraZeneca, BMS, Lilly, MSD, Novartis, Pfizer, Roche, Sandoz, Sanofi, Sevier, and Takeda, outside of the submitted work.Marco Danova has received personal fees for advisory roles, speaker engagements, and travel and accommodation expenses from Accademia Nazionale di Medicina, AstraZeneca, Novartis, Roche, Sandoz, and Servier, outside of the submitted work. Michelino De Laurentiis has received personal fees for advisory roles, speaker engagements, and travel and accommodation expenses from Amgen, AstraZeneca, Celgene, Daiichi-Sankyo, Eisai, Exact Science, Eli Lilly, Gilead, Ipsen, Merck Sharp and Dohme, Novartis, Pfizer, Pierre Fabre, Roche, Sanofi, and Seagen, outside of the submitted work. Paolo Marchetti has received research funding from Roche, Merck Sharp and Dohme, Bristol Myers Squibb, AstraZeneca, Boehringer Ingelheim, Novartis, and Pfizer and personal fees from Roche, Merck Sharp and Dohme, Bristol Myers Squibb, Eli Lilly, Novartis, and Pfizer. Carmine Pinto has received personal fees for advisory roles, speaker engagements, and travel and accommodation expenses from Amgen, Astellas, AstraZeneca, Bayer, Bristol Myers Squibb, Celgene, Clovis Oncology, Eisai, Ipsen, Janssen, Incyte, Merck-Serono, Merck Sharp and Dohme, Novartis, Roche, Sandoz, Sanofi, and Servier, outside of the submitted work. Lorenzo Antonuzzo and Giovanni Rosti have no competing interests to declare that are relevant to the content of this article.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}]}}